Azora Files $250M Shelf and $20M Jefferies ATM, Replacing A.G.P. Program
AZR has more than doubled off its 52-week low of $1.31 on light trading volume (0.2× avg).
Summary
Azora registered up to $250 million of securities and a $20 million at-the-market program with Jefferies, replacing its terminated A.G.P. ATM. No shares have been sold yet, and the small public float caps how much can actually be raised in any 12-month window.
Key Events · Financing and Capital Events · AZR
-
New $250M Shelf and $20M ATM
A Form S-3 registers up to $250,000,000 of common stock, preferred stock, debt securities, warrants and units, including a $20,000,000 at-the-market program with Jefferies under an Open Market Sale Agreement dated November 16, 2026.
-
Prior ATM Terminated
On November 14, 2026, the company terminated its existing At-the-Market Offering Agreement dated August 1, 2025 with A.G.P./Alliance Global Partners; no additional sales will be made under it.
-
Float Cap Limits Near-Term Sales
Public float is $64,163,568 (12,705,657 non-affiliate shares at $5.05 on October 28, 2026), so while float stays below $75 million primary sales are capped at one-third of float per 12 months; $1,275,175 has already been sold under that rule in the trailing twelve months.
-
Agent Compensation Terms
Jefferies receives up to 3.0% of gross sales price, reimbursement of up to $100,000 in counsel fees at signing plus up to $30,000 per diligence bringdown, and the company estimates roughly $200,000 in offering expenses excluding commissions.
Analysis · AZR · Life Sciences
Azora has registered the capacity to sell up to $250 million of securities over time, including up to $20 million of common stock through Jefferies as sales agent. No shares have been sold under either facility; each actual sale requires a prospectus supplement, so this is permission to raise capital, not a completed raise. The timing matters: the company just reported a Q3 2026 net loss of $64.6 million, and its lead program AT177 is still in IND-enabling studies with an IND filing and Phase 1a trial planned for the first half of 2027. That is an expensive runway to fund, and the ATM is the mechanism to do it. Because public float is $64.2 million, General Instruction I.B.6 caps primary sales at one-third of float in any 12-month period, so the practical near-term raise is far smaller than the headline $250 million. The company also terminated its prior A.G.P. at-the-market agreement on November 14, 2026, so this is a replacement agent relationship rather than a second, stacked program.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZR was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.4M. The 52-week trading range was $1.31 to $8.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.